Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression.

MLA

Aoki, Yusuke, et al. “Reduced Malignancy of Super Methotrexate-Resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/MTOR and c-MYC Expression.” Anticancer Research, vol. 44, no. 7, July 2024, pp. 2787–92. EBSCOhost, https://doi.org/10.21873/anticanres.17090.

APA

Aoki, Y., Kubota, Y., Masaki, N., Obara, K., Tome, Y., Bouvet, M., Nishida, K., & Hoffman, R. M. (2024). Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression. Anticancer Research, 44(7), 2787–2792. https://doi.org/10.21873/anticanres.17090

Chicago

Aoki, Yusuke, Yutaro Kubota, Noriyuki Masaki, Koya Obara, Yasunori Tome, Michael Bouvet, Kotaro Nishida, and Robert M Hoffman. 2024. “Reduced Malignancy of Super Methotrexate-Resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/MTOR and c-MYC Expression.” Anticancer Research 44 (7): 2787–92. doi:10.21873/anticanres.17090.